CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash Flows from Operating Activities
Net income	$ 9,173	$ 7,414
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2,721	2,716
Intangible asset impairment charges	35	864
Charge for acquisition of Peloton Therapeutics, Inc.	0	982
Deferred income taxes	47	(386)
Share-based compensation	354	306
Other	(445)	219
Net changes in assets and liabilities	(5,638)	(3,469)
Net Cash Provided by Operating Activities	6,247	8,646
Cash Flows from Investing Activities
Capital expenditures	(3,170)	(2,336)
Purchases of securities and other investments	(78)	(2,380)
Proceeds from sales of securities and other investments	1,894	7,459
Acquisition of ArQule, Inc., net of cash acquired	(2,545)	0
Acquisition of Antelliq Corporation, net of cash acquired	0	(3,620)
Acquisition of Peloton Therapeutics, Inc., net of cash acquired	0	(1,040)
Other acquisitions, net of cash acquired	(907)	(269)
Other	141	320
Net Cash Used in Investing Activities	(4,665)	(1,866)
Cash Flows from Financing Activities
Net change in short-term borrowings	(311)	(3,892)
Payments on debt	(1,954)	0
Proceeds from issuance of debt	4,419	4,958
Purchases of treasury stock	(1,281)	(3,730)
Dividends paid to stockholders	(4,673)	(4,290)
Proceeds from exercise of stock options	68	344
Other	(472)	(240)
Net Cash Used in Financing Activities	(4,204)	(6,850)
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	89	(26)
Net Decrease in Cash, Cash Equivalents and Restricted Cash	(2,533)	(96)
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $258 at January 1, 2020 included in Other Assets)	9,934	7,967
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $45 at September 30, 2020 included in Other Assets)	$ 7,401	$ 7,871